Can Ozempic, Wegovy, Mounjaro, and Other GLP-1 Medications Help People Quit Smoking?
Smoking cessation is one of the single most impactful things a person can do for their long-term health, and one of the most difficult. Nicotine addiction alters the brain’s reward circuitry in ways that survive the last cigarette by months — the neurological patterns that drove smoking remain, even after the pharmacological withdrawal resolves, creating a vulnerability to relapse that persists long after quitting feels manageable.
Since GLP-1 receptor agonists entered widespread clinical use, a pattern has emerged in the reports of patients who smoke: many describe losing interest in cigarettes without planning to. They smoke fewer automatically, find that cigarettes have become less satisfying, or simply forget to smoke in situations where they would previously have done so without thinking. Some describe quitting without difficulty that previous attempts had never achieved.
The working hypothesis is that GLP-1 receptor activation in the brain’s reward circuitry reduces the dopaminergic signal that makes nicotine reinforcing — the same mechanism that appears to reduce food cravings and alcohol interest in other patients. The neuroscience of this mechanism is covered in full in the GLP-1 drugs and dopamine article; this article applies that framework specifically to nicotine and smoking.
GLP-1 medications are not approved as smoking cessation treatments. Patients who want to quit smoking should speak with their healthcare provider about established options, including varenicline, bupropion, and nicotine replacement therapy. Do not stop prescribed smoking cessation medications without medical guidance.
Why Nicotine Addiction Is So Difficult to Overcome
Nicotine is one of the most addictive substances encountered in everyday life, and its difficulty as a cessation target reflects the sophistication of the neurological adaptations it produces. Understanding these adaptations is important for evaluating what GLP-1 drugs might plausibly do.
Nicotine enters the bloodstream within seconds of inhalation and reaches the brain almost immediately, binding to nicotinic acetylcholine receptors in the ventral tegmental area and triggering dopamine release in the nucleus accumbens. The dopamine release is the reinforcing signal: it feels rewarding, it associates the act of smoking with that reward, and it creates anticipatory craving that drives the next cigarette. Over time, the brain downregulates nicotinic acetylcholine receptors and reduces dopamine sensitivity in a process of neuroadaptation that makes normal daily functioning feel inadequate without nicotine — a state that smokers experience as “needing” a cigarette.
Withdrawal from nicotine produces an uncomfortable cluster of symptoms: irritability, anxiety, difficulty concentrating, increased appetite, restlessness, and dysphoria that can persist for weeks and that constitutes one of the primary drivers of relapse. Even after withdrawal resolves, the neurological vulnerability to cue-triggered craving remains. Environmental cues that have been paired with smoking — coffee, alcohol, work breaks, social situations, emotional stress — can trigger powerful reinstatement of smoking urges months or years after quitting, because the conditioned dopaminergic response to those cues was never extinguished.
Current Smoking Cessation Treatments and Their Limitations
The evidence-based pharmacological options for smoking cessation include nicotine replacement therapy, varenicline, and bupropion. Each works through a different mechanism, and their effectiveness varies substantially across individuals. Varenicline — a partial agonist at the nicotinic acetylcholine receptor — is generally considered the most effective single pharmacological agent, producing abstinence rates roughly two to three times higher than placebo in clinical trials. Nicotine replacement therapy in its various forms addresses withdrawal but does not fully address the cue-triggered craving that drives long-term relapse. Behavioral counseling and cessation programs add meaningful benefit on top of pharmacotherapy.
Even with the best available treatment, the majority of quit attempts fail within a year. Long-term abstinence rates remain modest despite decades of clinical effort, reflecting the durability of nicotine’s neurological effects and the power of the environmental cues that maintain smoking behavior. There is a genuine unmet need for additional pharmacological options, and it is this treatment gap that has made the GLP-1 and nicotine research program clinically interesting rather than simply scientifically curious.
How GLP-1 Receptor Activation May Affect Nicotine Reward
The overlap between the neural architecture of nicotine addiction and the distribution of GLP-1 receptors in the brain is the anatomical basis of the research hypothesis. GLP-1 receptors are expressed in the ventral tegmental area — where nicotine triggers dopamine-producing neuron activity — and in the nucleus accumbens, where that dopamine produces the reinforcing reward signal. When GLP-1 receptor agonists activate these receptors, they may modulate the mesolimbic dopamine response to nicotine in ways that reduce how rewarding smoking feels. This is the same mechanism proposed for the drug’s effects on food, alcohol, and other rewarding stimuli, covered in detail in the compulsive behaviors overview.
The four specific mechanisms most actively being studied are:
Reduced Nicotine Reward
GLP-1 receptor activation in the nucleus accumbens may reduce the dopaminergic response to nicotine itself, making smoking feel less rewarding without eliminating the sensory experience of it. Patients describe this as cigarettes “just not hitting the same way” — the act is unchanged but the subjective reward has diminished. If the reinforcing value of smoking is reduced, the neurological signal that drives the next cigarette is weakened, and the smoking behavior becomes less compulsive over time.
Blunted Cue-Triggered Craving
Cue-triggered craving — the powerful urge to smoke produced by environmental situations previously associated with cigarettes — is the primary driver of long-term relapse, and it is the dimension of nicotine addiction that existing treatments address least reliably. GLP-1 receptor activation in the amygdala and hippocampus, where cue-reward associations are encoded, may reduce the emotional salience of smoking-associated cues. Animal studies have consistently found reduced cue-induced reinstatement of nicotine-seeking following GLP-1 receptor agonist treatment — suggesting that the triggers that reliably produce craving become less effective. This is clinically significant because cue-triggered relapse accounts for the large majority of failures in long-term cessation.
Reduced Stress-Triggered Smoking
Stress is one of the most powerful and most treatment-resistant triggers of smoking relapse. The neurobiological link between stress and nicotine-seeking runs through corticotropin-releasing factor circuits that interact with dopamine reward pathways in ways that reliably reinstate drug-seeking after periods of abstinence. GLP-1 receptors in the hypothalamus and brainstem are involved in HPA axis regulation, and GLP-1 receptor activation may modulate stress reactivity in ways that reduce the degree to which stress specifically triggers the urge to smoke. This is consistent with patient reports of feeling calmer under stress during GLP-1 therapy, covered in more depth in the emotional regulation article.
Strengthened Executive Control
GLP-1 receptor activation in the prefrontal cortex may support the inhibitory control that allows smokers to resist the automatic urge to light a cigarette when triggered by cues or stress. By either reducing the limbic drive toward smoking or strengthening the prefrontal capacity to override it — or both — GLP-1 drugs may improve the balance between the automatic and deliberate systems that ultimately determines whether a quit attempt succeeds. The impulse control and self-control articles cover this mechanism in the broader context of behavioral regulation.
What the Research Currently Shows
Animal Studies
The preclinical evidence for GLP-1 drugs’ effects on nicotine reward is consistent across multiple research groups, multiple GLP-1 receptor agonist compounds, and multiple experimental paradigms. Rodent studies have found reduced voluntary nicotine self-administration, decreased nicotine-seeking behavior in conditions where the drug is not available, blunted cue-induced reinstatement of nicotine-seeking after abstinence, and reduced nicotine-conditioned place preference. The consistency across compounds — findings have been replicated with exendin-4, liraglutide, and semaglutide among others — is particularly notable because it points toward a class-level pharmacological effect rather than a property specific to one agent.
Particularly interesting are studies examining relapse-like behavior. When animals that had self-administered nicotine were given access to smoking cues after a period of forced abstinence, those treated with GLP-1 receptor agonists showed substantially reduced reinstatement of nicotine-seeking compared to controls. This cue-reinstatement finding is the one with the most direct clinical relevance, because cue-triggered relapse is the defining challenge of long-term human smoking cessation.
Human Evidence
Human evidence is at an earlier stage. The most substantial available data comes from large healthcare database analyses finding lower rates of smoking and nicotine-related diagnoses in patients treated with GLP-1 medications compared to matched patients on other diabetes or obesity treatments. These observational findings are directionally consistent with the animal literature and with patient reports, but they cannot establish causation and are subject to confounding by the multiple ways GLP-1 drug users differ from comparator populations.
Several randomised controlled trials specifically examining GLP-1 drugs as smoking cessation aids are now in various stages of development and enrollment. These trials — designed to test whether GLP-1 receptor agonists reduce cigarettes per day, increase abstinence rates, or reduce relapse in patients motivated to quit — will provide the definitive human evidence. Their results are expected to substantially change the clinical picture over the next several years.
The most important thing the current human evidence establishes is that there is a consistent signal worth testing in controlled trials. What it cannot yet establish is whether GLP-1 drugs are effective cessation aids at the population level, what dose and duration of treatment would be required, or which patients benefit most.
A Clinically Distinctive Advantage: Managing Post-Cessation Weight Gain
Weight gain after quitting smoking is one of the most frequently cited reasons smokers either don’t attempt cessation or relapse after initial success. The weight gain is real — on average, former smokers gain 4 to 5 kilograms in the year after quitting, reflecting both the removal of nicotine’s appetite-suppressing and metabolic effects and the compensatory increase in food intake that many ex-smokers experience.
For patients who are already managing obesity or overweight and who are prescribed GLP-1 medications for that indication, the appetite suppression and weight management effects of GLP-1 therapy could provide a meaningful protective effect against post-cessation weight gain. This is not a reason to use GLP-1 drugs as smoking cessation medications in patients who don’t otherwise qualify for them, but it is a potentially significant advantage for the patient who is already on GLP-1 therapy for metabolic reasons and who is attempting to quit smoking simultaneously.
Whether this protective effect is sufficient to reduce the weight-related barrier to cessation in patients who would otherwise use it as a reason not to quit is a clinical question worth exploring in the context of treatment planning, even before clinical trials establish GLP-1 drugs as formal cessation aids.
Does the Evidence Extend to Vaping and E-Cigarettes?
Nicotine addiction is not delivery-method specific. Whether nicotine is inhaled as cigarette smoke, vapour from an e-cigarette, or absorbed through smokeless tobacco, the neurological adaptations it produces are comparable. The dopaminergic reinforcement mechanism, the cue conditioning, and the withdrawal symptoms are all features of nicotine addiction rather than of any particular delivery format.
This means the GLP-1 hypothesis applies in principle to vaping addiction as much as to cigarette smoking. If GLP-1 receptor activation reduces the reward value of nicotine and blunts cue-triggered craving, those effects should not discriminate between how the nicotine was delivered. Human research specifically examining GLP-1 effects on vaping and e-cigarette use is limited, reflecting the general state of the field rather than any reason to believe the mechanism would not generalise. As the broader substance use disorders research program advances, vaping-specific data is expected to be incorporated.
How GLP-1 Therapy Might Fit Alongside Existing Cessation Treatments
The most likely clinical role for GLP-1 receptor agonists in smoking cessation — if clinical trials support their effectiveness — is as an adjunct to rather than a replacement for existing treatments. Varenicline, nicotine replacement therapy, and behavioral counseling each address different dimensions of nicotine addiction. GLP-1 drugs, through their effects on reward circuit modulation and cue reactivity, would be targeting mechanisms that existing treatments do not directly engage, making a complementary rather than competitive positioning pharmacologically logical.
Particularly interesting is the potential combination with varenicline. Varenicline works as a partial agonist at the nicotinic acetylcholine receptor, reducing both withdrawal and the reward of nicotine when smoked. GLP-1 receptor activation would be operating through the downstream dopamine circuitry that nicotinic receptor activity feeds into, potentially producing additive effects on reducing nicotine reward. This combination hypothesis is worth investigating in trials, though evidence currently does not exist to recommend it in practice.
Frequently Asked Questions
Can Ozempic help people quit smoking?
Some patients on Ozempic report reduced nicotine cravings and smoking fewer cigarettes without trying. Ozempic is not approved as a smoking cessation medication, and the evidence from human clinical trials is not yet sufficient to recommend it for this purpose. Clinical trials are underway. Patients who want to quit should discuss established options — varenicline, nicotine replacement therapy, bupropion — with their healthcare provider.
Why do GLP-1 drugs affect smoking?
GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens — the brain regions where nicotine triggers dopamine release and reinforcement. GLP-1 receptor activation in these areas appears to modulate the dopaminergic reward response to nicotine, reducing how rewarding smoking feels. The same mechanism appears to underlie the reductions in food cravings, alcohol interest, and other compulsive behaviors that patients on these medications describe.
Should I stop my smoking cessation medication if I start Wegovy?
No. Never discontinue prescribed smoking cessation medications without consulting your healthcare provider. GLP-1 drugs are not approved as cessation medications and should not be substituted for treatments your provider has prescribed for that purpose. If you are on both a GLP-1 drug and a smoking cessation medication, discuss any changes with your prescriber.
Could GLP-1 drugs help with vaping addiction?
In principle, the mechanism proposed for GLP-1 drugs’ effects on cigarette smoking would apply to vaping as well, since nicotine addiction operates similarly regardless of delivery method. Human evidence specifically addressing GLP-1 effects on vaping is limited. As clinical research on GLP-1 drugs and nicotine dependence advances, vaping-specific data is expected to emerge.
Is the weight gain after quitting smoking reduced by GLP-1 drugs?
For patients already taking GLP-1 medications for obesity or metabolic reasons, the appetite-suppressing and weight-management effects of the medication may provide some protection against the post-cessation weight gain that deters many smokers from attempting to quit. This is a potential clinical advantage rather than a reason to prescribe GLP-1 drugs specifically for smoking cessation.
When will we have definitive clinical trial results?
Randomised controlled trials specifically evaluating GLP-1 drugs as smoking cessation aids are in various stages of design, enrollment, and follow-up. Given the minimum follow-up periods needed to assess cessation and relapse, meaningful results are expected over the next two to three years. This page will be updated as findings become available.
Key Takeaways
The GLP-1 and smoking cessation research represents a promising but not yet clinically established area that has generated genuine interest in addiction medicine. The most important points from this article are:
- Nicotine addiction is driven by dopaminergic reinforcement in the mesolimbic reward circuit — the same circuitry in which GLP-1 receptors are expressed
- Many patients on GLP-1 medications spontaneously report reduced nicotine cravings and smoking less, without making a deliberate cessation effort
- Animal studies consistently show reduced nicotine self-administration, decreased nicotine reward, blunted cue-induced reinstatement, and reduced stress-triggered relapse following GLP-1 receptor agonist treatment
- Human observational evidence is directionally consistent; large randomised controlled trials are now underway and will provide the definitive human evidence
- The four proposed mechanisms — reduced nicotine reward, blunted cue-triggered craving, reduced stress-driven smoking, and strengthened executive control — are each plausible and may operate simultaneously
- GLP-1 drugs are not approved as smoking cessation medications and should not replace established treatments including varenicline, nicotine replacement therapy, and counselling
- Post-cessation weight gain management may represent a distinctive clinical advantage for patients already on GLP-1 therapy who are attempting to quit
- The mechanism, if confirmed, would also be expected to apply to vaping and other nicotine delivery formats